Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?
AbstractEpithelial ovarian cancer (EOC) is the leading cause of death for gynecological cancer. The standard treatment for advanced stage is the combination of optimal debulking surgery and platinum-based chemotherapy. Nevertheless, recurrence is frequent (around 70%) and prognosis is globally poor. New therapeutic agents are needed to improve survival. Since EOC is strongly immunogenic, immune checkpoint inhibitors are under evaluation for their capacity to contrast the “turn off” signals expressed by the tumor to escape the immune system and usually responsible for self-tolerance maintenance. This article reviews the literature on anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), anti-PD-1, anti-PD-L1, and anti-PD-L2 antibodies in EOC and highlights their possible lines of development. Further studies are needed to better define the prognostic role of the immune checkpoint inhibitors, to identify predictors of response and the optimal clinical setting in EOC. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Mittica, G.; Genta, S.; Aglietta, M.; Valabrega, G. Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer? Int. J. Mol. Sci. 2016, 17, 1169.
Mittica G, Genta S, Aglietta M, Valabrega G. Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer? International Journal of Molecular Sciences. 2016; 17(7):1169.Chicago/Turabian Style
Mittica, Gloria; Genta, Sofia; Aglietta, Massimo; Valabrega, Giorgio. 2016. "Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?" Int. J. Mol. Sci. 17, no. 7: 1169.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.